title: Effects of glucagon-like peptide-1 (7-36) amide on neurohypophysial hormone secretion induced by acute hyperosmotic challenge.
abstract: This study was designed to investigate possible effects of glucagon-like peptide-1 (7-36) amide on the vasopressin and oxytocin release induced by acute peripheral or central osmotic stimulation. In the first series of experiments, rats were injected intraperitoneally with the isotonic (0.15 M) or hypertonic (1.5 M) NaCl solution and then, intracerebroventricularly, with either 1 microg glucagon-like peptide-1 (7-36) amide dissolved in 5 microl of isotonic saline or with the vehicle only. In the second study, 1 microg glucagon-like peptide-1 (7-36) amide, dissolved in isotonic or hypertonic (0.6 M) saline, was injected into the cerebroventricular system. Control rats were treated with isotonic or hypertonic saline only. All the animals were decapitated 10 min after the intracerebroventricular injection. Glucagon-like peptide-1 (7-36) amide enhanced significantly the basal secretion of vasopressin and oxytocin. Moreover, this peptide increased additionally the release of both neurohypophysial hormones stimulated previously by peripheral osmotic challenge. On the other hand, the peptide increased the oxytocin but not vasopressin secretion brought about by an intracerebroventricular injection of hypertonic saline thus suggesting that the central osmotic stimulation decreases the sensitivity of vasopressin neurons to glucagon-like peptide-1 (7-36) amide. It is concluded that glucagon-like peptide-1 (7-36) amide may affect the secretory activity of the hypothalamo-neurohypophysial system under acute osmotic challenge.
authors.affiliation: Department of Pathophysiology, The Medical University of Lodz, 60 Narutowicza Street, PL-90-136 Lodz, Poland. ebojanow@mail.bg.am.lodz.pl
authors.forename: E
authors.initials: E
authors.lastname: Bojanowska
authors.forename: B
authors.initials: B
authors.lastname: Stempniak
mesh_terms: D000818:Animals; D005934:Glucagon / Q000494:pharmacology*; D052216:Glucagon-Like Peptide 1; D006982:Hypertonic Solutions; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D008297:Male; D009997:Osmotic Pressure; D010121:Oxytocin / Q000097:blood / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology*; D010904:Pituitary Gland, Posterior / Q000378:metabolism*; D010909:Pituitary Hormones, Posterior / Q000378:metabolism*; D011498:Protein Precursors / Q000494:pharmacology*; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D014667:Vasopressins / Q000097:blood / Q000378:metabolism
chemical_list: D006982:Hypertonic Solutions; D010446:Peptide Fragments; D010909:Pituitary Hormones, Posterior; D011498:Protein Precursors; D014667:Vasopressins; D010121:Oxytocin; D052216:Glucagon-Like Peptide 1; D005934:Glucagon